First JCA on Tovorafenib/OJEMDA: what the report shows for the Delta-Dossier

For manufacturers, this first JCA is more than an individual assessment procedure. It provides an early practical test of how European evidence is prepared in a joint clinical assessment – and where the subsequent national translation work begins.

The Tovorafenib case shows that a JCA report does not automatically provide a fully robust basis for German benefit assessment. Several populations and eight PICOs were defined in the procedure. However, assessable comparative evidence was ultimately very limited.

Comparative evidence was mainly considered for one PICO: patients with BRAF V600E mutation, older than one year, compared with dabrafenib plus trametinib. For the full claimed indication and several individualised comparator therapies, robust comparative data were not available.

An additional matching-adjusted indirect comparison was submitted for another assessment question, but it was not included in the assessment because information on the comparator study was insufficient. The first JCA therefore illustrates clearly that methodological transferability from European evidence to national assessment questions cannot be assumed.

For Germany, the core challenge is not the formal act of referencing the JCA report. The decisive question is which parts of the European evidence package actually fit the German AMNOG assessment question, the appropriate comparator therapy and nationally accepted endpoints.

This is where the Delta-Dossier becomes relevant. It needs to show transparently which JCA contents are robust for Germany, where evidence gaps remain and which additional analyses, justifications or updates are required.

The Tovorafenib JCA also shows that endpoint applicability to German benefit assessment cannot simply be taken for granted. For outcomes such as tumour response or progression, the assessment may depend heavily on how the endpoint was measured, operationalised and analysed.

For the Delta-Dossier, it is therefore not sufficient to transfer results from the European report in a formal way. What matters is a clear explanation of what was measured, how the result was generated and whether this operationalisation fits the German assessment question.

This is particularly relevant for patient-relevant endpoints, the transferability of study results to the German care context and the handling of uncertainty in indirect comparisons or single-arm evidence.

The first JCA does not show that national dossiers will automatically become leaner. It shows that national dossier work under EU HTA will need to become more precise.

If the European evidence base is fragmented, covers only selected PICO questions or remains methodologically uncertain, additional explanation will be needed in the national procedure. For Germany, this concerns the appropriate comparator therapy, subgroups, endpoint relevance, evidence currency and the methodological robustness of comparative analyses.

The first JCA on Tovorafenib/OJEMDA is an important practical test for the new EU HTA environment. It demonstrates that the value of a Delta-Dossier does not lie in maximising references to the European report, but in translating European evidence into a form that can support national decision-making.

For manufacturers, this means that JCA readiness alone will not be sufficient. The key task is to assess early which European evidence components can carry weight in Germany, which gaps need to be addressed and how uncertainty can be explained in the German benefit assessment and negotiation context.

The first JCA on Tovorafenib/OJEMDA is particularly relevant because it makes several key EU HTA implementation questions visible in practice: how to handle limited evidence, how to address individualised comparator therapies, how to assess the limitations of indirect comparisons and how to transfer European PICO structures into national HTA procedures.

For the Delta-Dossier, this creates a clear task. It is not enough to document that a JCA report exists. The dossier needs to explain which JCA evidence is usable for Germany, which evidence does not carry sufficient weight and which national additions are required for the AMNOG procedure.